Genelux Ownership | Who Owns Genelux?
Genelux Ownership Summary
Genelux is owned by 11.01% institutional investors, 10.89% insiders, and 78.10% retail investors. Woodward diversified capital is the largest institutional shareholder, holding 5.69% of GNLX shares.
GNLX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Genelux | 11.01% | 10.89% | 78.10% |
| Sector | Healthcare Stocks | 232.86% | 10.65% | -143.51% |
| Industry | Biotech Stocks | 382.13% | 10.41% | -292.54% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Woodward diversified capital | 2.12M | 5.69% | $5.91M |
| Vanguard group | 1.55M | 4.09% | $6.76M |
| Bleichroeder lp | 714.00K | 1.88% | $3.00M |
| Blackrock funding, inc. /de | 385.31K | 1.02% | $1.68M |
| Geode capital management | 381.41K | 1.01% | $1.66M |
| Flputnam investment management | 280.90K | 0.76% | $679.79K |
| Alyeska investment group | 285.00K | 0.75% | $1.20M |
| Vanguard fiduciary trust | 251.61K | 0.68% | $608.90K |
| Cm management | 250.00K | 0.67% | $605.00K |
| Global retirement partners | 217.09K | 0.57% | $946.52K |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Woodward diversified capital | 2.12M | 2.69% | $5.91M |
| Bleichroeder lp | 714.00K | 0.58% | $3.00M |
| Cm management | 250.00K | 0.51% | $605.00K |
| Lifesteps financial | 118.86K | 0.18% | $287.65K |
| Provident wealth management | 155.67K | 0.11% | $376.72K |
| 5t wealth | 19.70K | 0.02% | $47.68K |
| Global retirement partners | 217.09K | 0.02% | $946.52K |
| Falcon wealth planning | 63.19K | 0.01% | $152.91K |
| Kwb wealth | 23.33K | 0.01% | $101.71K |
| Flputnam investment management | 280.90K | 0.01% | $679.79K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vanguard fiduciary trust | 251.61K | 0.00% | 251.61K |
| Cm management | 250.00K | 0.51% | 250.00K |
| Woodward diversified capital | 2.12M | 2.69% | 184.47K |
| Goldman sachs group | 183.81K | 0.00% | 150.46K |
| Vanguard group | 1.55M | 0.00% | 132.07K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Heights capital management | - | - | -238.37K |
| Dauntless investment group | - | - | -123.19K |
| Omers administration | - | - | -79.70K |
| Squarepoint ops | - | - | -58.57K |
| Paloma partners management | - | - | -50.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard fiduciary trust | 251.61K | 0.00% | 251.61K | $608.90K |
| Cm management | 250.00K | 0.51% | 250.00K | $605.00K |
| Barclays | 82.60K | 0.00% | 82.60K | $360.15K |
| Vanguard global advisers | 16.01K | - | 16.01K | $38.74K |
| Cassaday & co wealth management | 2.55K | 0.00% | 2.55K | $6.18K |
Sold Out
| Holder | Change |
|---|---|
| Allworth financial lp | -162.00 |
| Coldstream capital management | -175.00 |
| Point72 (difc) | -242.00 |
| Coppell advisory solutions | -3.00K |
| Point72 asia (singapore) pte. | -7.17K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -63.79% | 4,170,594 | -44.01% | 11 | 2.86% | 7 | -74.07% | 3 | -40.00% |
| Sep 30, 2025 | 28 | -54.10% | 4,415,257 | -40.27% | 11 | 3.07% | 7 | -73.08% | 3 | -72.73% |
| Jun 30, 2025 | 59 | -21.33% | 7,281,681 | -0.23% | 19 | 4.39% | 25 | -46.81% | 12 | 9.09% |
| Mar 31, 2025 | 74 | 29.82% | 7,269,064 | 49.24% | 20 | 9.55% | 46 | 130.00% | 11 | -42.11% |
| Dec 31, 2024 | 57 | 1.79% | 4,870,849 | -6.84% | 14 | 6.44% | 20 | -4.76% | 19 | 11.76% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 25, 2026 | Smalling Ralph | Head of Regulatory | Sell | $602.40 |
| Mar 24, 2026 | Smalling Ralph | Head of Regulatory | Sell | $834.90 |
| Mar 24, 2026 | Cappello Joseph | Chief Technical Officer | Sell | $2.19K |
| Mar 24, 2026 | Yu Yong | SVP, Clinical Development | Sell | $2.19K |
| Mar 24, 2026 | Zindrick Thomas | President and CEO | Sell | $8.67K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 6 |
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | - |
| 2025 Q2 | - | 5 |
| 2025 Q1 | - | - |
GNLX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools